We receive funding from a variety of sources that recognize the value of our high-impact research.
Jahan Porhomayon, MD, FCCP, FCCM
A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects with Staphylococcus aureus Bacteremia Including Infective Endocarditis. Jahan Porhomayon (Principal Investigator) 1/1/2015-1/1/2020.
A randomized, Double-blind, Placebo-controlled, Phase 3 study to assess the safety and efficacy of ART-123 in subjects with severe sepsis and coagulopathy. Jahan Porhomayon (Principal Investigator) 1/1/2015-1/1/2019.